NLS Pharmaceutics Ltd. (NLS) Announces Notice of Allowance of two new Patents in North America Covering Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy further bolstering its Patent Portfolio

Switzerland, July 3, 2019 - NLS Pharmaceutics Ltd. (NLS), a Swiss biotech firm focusing on the development of novel treatments for the Central Nervous System (CNS) in particular Attention Deficit Hyperactivity Disorder (ADHD) as well as Central Hypersomnias (including narcolepsy, idiopathic hypersomnia and Kleine Levin Syndrome) and other rare neurological diseases, today announced that the United States Patent and Trademark Office (USPTO) and the Canadian Intellectual Property Office (CIPO) have issued a Notice of Allowance for two new separate patent families.

U.S. Patent Application No. 15/913,481, entitled PHACETOPERANE FOR TREATING OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (inventor: NLS Co-founder Eric Konofal and Bruno Figadère), was allowed by the USPTO on June 26, 2019. The allowed invention claims a method for treating ADHD with phacetoperane, in particular levophacetoperane, or a pharmaceutically acceptable salt thereof. The specification also discloses other inventive concepts related to phacetoperane, which may be pursued in a subsequently filed continuing application at the USPTO. The U.S. patent to be issued expires in November 2032.

“It is hoped that phacetoperane will succeed methylphenidate at least because of its safety profile,” said Eric Konofal, MD, PhD.

In addition, Canadian Patent No. 2,825,275, entitled LAUFLUMIDE AND THE ENANTIOMERS THEREOF, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF (inventor: NLS Co-founder Eric Konofal), was allowed by the CIPO on May 30, 2019. The allowed invention claims inventive concepts related to the use of lauflumide or the enantiomers thereof in the treatment of ADHD, narcolepsy or idiopathic hypersomnia. The Canadian patent to be issued expires in January 2032.

“We are extremely pleased with the continued development of our patent portfolio. The issuance of these patents is another major step in the development of a robust patent portfolio of NLS, including for the treatment of ADHD and narcolepsy, both fast growing neurological disorders with high unmet medical needs,” said Alex Zwyer, Chief Executive Officer of NLS.
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics is a privately owned, Swiss-based biotech firm focusing on the development of new treatments for ADHD, sleep disorders, cognitive impairment and other neurological disorders that remain largely under-diagnosed and for which unmet medical needs are significant. NLS has built a large portfolio of promising non-clinical and clinical-stage compounds being developed by an experienced team of proven experts in ADHD and sleep related disorders and working closely with key opinion leaders. NLS Pharmaceutics lead compound Nolazol® (mazindol) completed a phase 2 study in the US in adult subjects with ADHD demonstrating best-in-class efficacy and a favorable safety profile.

Safe Harbor Statement
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, when NLS states that it is hoped that phacetoperane will succeed methylphenidate at least because of its safety profile, it is using forward-looking statements. These forward-looking statements and their implications are based on the current expectations of the management of NLS only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles in launching and/or successfully completing its clinical trials; NLS’s products may not be approved by regulatory agencies, NLS’s technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with NLS’s process; NLS’s products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; NLS’s patents may not be sufficient; NLS’s products may harm recipients; changes in legislation may adversely impact NLS; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of NLS to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Investor relations contact
LifeSci Advisors - Daniel Ferry: +1 617-535-7746

Partnering contact
NLS Pharmaceutics Pharma - Alex Zwyer, CEO: +41 41 618 80 00

www.nlspharma.com